Drug Eluting Stent for High-risk Patients

Using an in-vivo model, researchers at the University of Strathclyde have found that restenosis can be prevented by a novel, proprietary compound with no harmful effects on endothelial properties. VAN-10-4, a novel small molecule, exerts a marked protection against the development of restenosis when applied as a drug-eluting stent or given as a short-term local infusion. VAN-10-4's superior activity is not confined to its ability to reduce neointimal formation; in-vitro studies also showed that VAN-10-4 had no detrimental effect on contractile or relaxant function of blood vessels. VAN-10-4 is significantly more effective as an inhibitor of smooth muscle cell proliferation than paclitaxel. Furthermore, VAN-10-4 is equally effective at inhibiting p42/p44 MAPK activation in human and porcine artery cells, suggesting that its effects should be evident in the clinical setting. The use of VAN-10-4 on a drug-eluting stent holds great promise as a superior stent for high risk patients.

Key Benefits

Prevention of restenosis in artery stents
Designed for diabetic and high risk patients
Novel anti-proliferative mechanism
No detrimental effects on endothelial cell function or artery contractility
Enhanced efficacy and reduced toxicity compared with competitor compounds
Compound has cleared regulatory toxicology (data available)

Applications

This technology can be used for any procedure which carries the risk of restenosis, from angioplasty to artery reconstruction, for medical and pharmaceutical markets.

IP Status

VAN 10-4 and its use in restenosis is covered by extensive patent filings including three granted US patents: 6,225,342; 6,313,099; and 6,498,152. The compound has also cleared regulatory toxicology testing. Contact is welcomed from organisations interested in developing, licensing or exploiting this technology.

If you would like further information about this opportunity please fill out the form below. Your enquiry will be passed on to the relevant University who will respond to you directly.

OPPORTUNITY	Drug Eluting Stent for High-risk Patients
NAME*
COMPANY NAME
COUNTRY
EMAIL*
TELEPHONE
	* denotes compulsory field

If you register you will receive automatic email notification of technologies in the sectors you indicate. Filling on the form takes only a few minutes and will ensure you are kept up to date with new additions to the university-technology website.